In another study, immunosuppression was reversed in the tumor microenvironment by applying an excess of positive LNPs carrying untargeted tumor RNA to prime the peripheral and intratumoral environment for response to immunotherapy, with systemic and intratumoral myeloid cells co-expressing PD-L1 and CD86. The gene discussed is CD86; the disease is neoplasm.